Subscribe to RSS
Download PDF
DOI: 10.1160/TH13-07-0603
Association of mean platelet volume with risk of venous thromboembolism and mortality in patients with cancer
Results from the Vienna Cancer and Thrombosis Study (CATS)Financial support: This study was supported by funds of the “Oesterreichische Nationalbank” (Anniversary Fund, project numbers 12739 and 14744).
Publication History
Received:
23 July 2013
Accepted after major revision:
26 October 2013
Publication Date:
29 November 2017 (online)
Summary
Venous thromboembolism (VTE) is a frequent complication in cancer patients. Mean platelet volume (MPV) has been associated with arterial and venous thrombosis in patients without cancer. We analysed MPV in cancer patients and investigated the association of MPV with risk of VTE and mortality. MPV was routinely determined in the Vienna Cancer and Thrombosis Study, a prospective, observational cohort study of patients with newly diagnosed or progressive cancer after remission. Study endpoints were occurrence of symptomatic VTE or death during a maximum follow-up of two years. Out of 1,544 included patients, 114 (7.4%) developed VTE and 573 (37.1%) died during a median observation time of 576 days. High MPV ≥75th percentile of the study population; ≥10.8 fL) was associated with decreased risk of VTE compared to MPV below the 75th percentile (HR [95% CI]: 0.59 [0.37–0.95], p=0.031). In multivariable analysis, including age, sex, cancer groups, newly diagnosed vs recurrent disease, platelet count and soluble P-selectin, this association remained statistically significant (0.65 [0.37–0.98], p=0.041). Mortality of patients with MPV (≥75th percentile was significantly decreased compared to those with lower MPV (0.72 [0.59–0.88], p=0.001). Two-year probability of VTE and overall survival was 5.5% and 64.7% in patients with high MPV compared to 9% and 55.7% in those with lower MPV. In conclusion, high MPV is associated with decreased VTE risk and improved survival in cancer patients. This finding is contrary to results observed in patients without cancer. Further studies are needed to confirm our results and elucidate underlying mechanisms.
Previous presentations of this manuscript: Data from this study were presented in part at the Annual Spring Meeting of the Austrian Society for Haematology and Oncology (OeGHO) in Linz, Austria, and as an oral presentation at the XXIV. Congress of the International Society on Thrombosis and Haemostasis (ISTH) 2013 in Amsterdam, the Netherlands.
-
References
- 1 Horsted F, West J, Grainge MJ. Risk of venous thromboembolism in patients with cancer: a systematic review and meta-analysis.. PLoS Med 2012; 9: e1001275.
- 2 Khorana AA. Venous thromboembolism and prognosis in cancer.. Thromb Res 2010; 125: 490-493.
- 3 Thaler J, Ay C, Pabinger I. Venous thromboembolism in cancer patients - Risk scores and recent randomised controlled trials.. Thromb Haemost 2012; 108: 1042-1048.
- 4 Khorana AA, Kuderer NM, Culakova E. et al. Development and validation of a predictive model for chemotherapy-associated thrombosis.. Blood 2008; 111: 4902-4907.
- 5 Simanek R, Vormittag R, Ay C. et al. High platelet count associated with venous thromboembolism in cancer patients: results from the Vienna Cancer and Thrombosis Study (CATS). J Thromb.. Haemost 2010; 8: 114-120.
- 6 Mandalä M, Barni S, Prins M. et al. Acquired and inherited risk factors for developing venous thromboembolism in cancer patients receiving adjuvant chemotherapy: a prospective trial.. Ann Oncol 2010; 21: 871-876.
- 7 Ay C, Simanek R, Vormittag R. et al. High plasma levels of soluble P-selectin are predictive of venous thromboembolism in cancer patients: results from the Vienna Cancer and Thrombosis Study (CATS).. Blood 2008; 112: 2703-2708.
- 8 Thompson CB, Eaton KA, Princiotta SM. et al. Size dependent platelet subpopu-lations: relationship of platelet volume to ultrastructure, enzymatic activity, and function.. Br J Haematol 1982; 50: 509-519.
- 9 Jakubowski JA, Thompson CB, Vaillancourt R. et al. Arachidonic acid metabolism by platelets of differing size.. Br J Haematol 1983; 53: 503-511.
- 10 Giles H, Smith RE, Martin JF. Platelet glycoprotein IIb-IIIa and size are increased in acute myocardial infarction.. Eur J Clin Invest 1994; 24: 69-72.
- 11 Leader A, Pereg D, Lishner M. Are platelet volume indices of clinical use? A multidisciplinary review.. Ann Med 2012; 44: 805-816.
- 12 Slavka G, Perkmann T, Haslacher H. et al. Mean platelet volume may represent a predictive parameter for overall vascular mortality and ischemic heart disease.. Arterioscler Thromb Vasc Biol 2011; 31: 1215-1218.
- 13 Bath P, Algert C, Chapman N. et al. Association of mean platelet volume with risk of stroke among 3134 individuals with history of cerebrovascular disease.. Stroke 2004; 35: 622-626.
- 14 Greisenegger S, Endler G, Hsieh K. et al. Is Elevated Mean Platelet Volume Associated With a Worse Outcome in Patients With Acute Ischemic Cerebro- vascular Events?. Stroke 2004; 35: 1688-1691.
- 15 Braekkan SK, Mathiesen EB, Njolstad I. et al. Mean platelet volume is a risk factor for venous thromboembolism: the Tromso study.. J Thromb Haemost 2010; 8: 157-162.
- 16 Ay C, Vormittag R, Dunkler D. et al. D-dimer and prothrombin fragment 1 + 2 predict venous thromboembolism in patients with cancer: results from the Vienna Cancer and Thrombosis Study.. J Clin Oncol 2009; 27: 4124-4129.
- 17 Fine JP, Gray RJ. A Proportional Hazards Model for the Subdistribution of a Competing Risk.. J Am Statistical Assoc 1999; 94: 496-509.
- 18 Mutlu H, Artis TA, Erden A. et al. Alteration in Mean Platelet Volume and Plati-crit Values in Patients With Cancer That Developed Thrombosis.. Clin Appl Thromb Hemost 2012; 19: 331-333.
- 19 Demirin H, Ozhan H, Ucgun T. et al. Normal range of mean platelet volume in healthy subjects: Insight from a large epidemiologic study.. Thromb Res 2011; 128: 358-360.
- 20 Vasse M, Masure A, Lenormand B. Mean platelet volume is highly correlated to platelet count.. Thromb Res 2012; 130: 559-560.
- 21 Boos CJ, Lip GYH. Assessment of mean platelet volume in coronary artery disease - what does it mean?. Thromb Res 2007; 120: 11-13.
- 22 Soranzo N, Rendon A, Gieger C. et al. A novel variant on chromosome 7q22.3 associated with mean platelet volume, counts, and function.. Blood 2009; 113: 3831-3837.
- 23 Bambace NM, Holmes CE. The platelet contribution to cancer progression.. J Thromb Haemost 2011; 9: 237-249.
- 24 Nash GF, Turner LF, Scully MF. et al. Platelets and cancer.. Lancet Oncol 2002; 3: 425-430.
- 25 Zhang W, Dang S, Hong T. et al. A humanized single-chain antibody against beta 3 integrin inhibits pulmonary metastasis by preferentially fragmenting activated platelets in the tumour microenvironment.. Blood 2012; 120: 2889-2898.
- 26 Bowles KM, Cooke LJ, Richards EM. et al. Platelet size has diagnostic predictive value in patients with thrombocytopenia.. Clin Lab Haematol 2005; 27: 370-373.
- 27 Mandalä M, Barni S, Prins M. et al. Acquired and inherited risk factors for developing venous thromboembolism in cancer patients receiving adjuvant chemotherapy: a prospective trial.. Ann Oncol 2010; 21: 871-876.